The DACT2 antibody is a specialized immunological tool targeting the Dishevelled-binding antagonist of β-catenin 2 (DACT2) protein, a regulator of Wnt/β-catenin and TGF-β signaling pathways. This antibody enables researchers to study DACT2's roles in embryonic development, cancer biology, and cardiovascular diseases. Validated across diverse applications, it is critical for detecting DACT2 expression, localization, and functional interactions in cellular and tissue contexts .
Tumor Suppression:
DACT2 antibodies identified reduced DACT2 expression in esophageal squamous cell carcinoma (ESCC) via immunohistochemistry (1:100 dilution; Abcam ab79042), correlating with poor differentiation and survival .
In nasopharyngeal carcinoma (NPC), DACT2 overexpression inhibited cell migration/invasion (via Transwell assays) and reduced MMP2/9 expression .
Breast cancer studies revealed DACT2 methylation-associated silencing, with antibody-based WB confirming re-expression suppressed tumor growth and metastasis .
Mechanistic Insights:
Atrial Fibrillation (AF):
STRING: 7955.ENSDARP00000078756
UniGene: Dr.80140